keyword
MENU ▼
Read by QxMD icon Read
search

Task force

keyword
https://www.readbyqxmd.com/read/28324697/adverse-events-in-a-chiropractic-spinal-manipulative-therapy-single-blinded-placebo-randomized-controlled-trial-for-migraineurs
#1
Aleksander Chaibi, Jūratė Šaltytė Benth, Peter J Tuchin, Michael Bjørn Russell
BACKGROUND: Unlike pharmacological randomized controlled trials (RCTs), manual-therapy RCTs do not always report adverse events (AEs). The few manual-therapy RCTs that provide information on AEs are frequently without details, such as the type and-, severity of the AE and reason for withdrawal. OBJECTIVE: To prospectively report all AEs in a chiropractic spinal manipulative therapy (CSMT) RCT. DESIGN: A prospective 3-armed, single-blinded, placebo, RCT...
March 14, 2017: Musculoskelet Sci Pract
https://www.readbyqxmd.com/read/28323843/dynamic-postural-control-and-associated-attentional-demands-in-contemporary-dancers-versus-non-dancers
#2
Geneviève Sirois-Leclerc, Anthony Remaud, Martin Bilodeau
Postural control is not a fully automatic process, but requires a certain level of attention, particularly as the difficulty of the postural task increases. This study aimed at testing whether experienced contemporary dancers, because of their specialized training involving the control of posture/balance, would present with a dual-task performance suggesting lesser attentional demands associated with dynamic postural control compared with non-dancers. Twenty dancers and 16 non-dancers performed a dynamic postural tracking task in both antero-posterior and side-to-side directions, while standing on a force platform...
2017: PloS One
https://www.readbyqxmd.com/read/28320011/trends-in-prostate-specific-antigen-screening-and-prostate-cancer-interventions-3-years-after-the-u-s-preventive-services-task-force-recommendation
#3
Mei-Sing Ong, Kenneth D Mandl
No abstract text is available yet for this article.
March 21, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28318402/ipsilateral-scapular-cutaneous-anchor-system-an-alternative-for-the-harness-in-body-powered-upper-limb-prostheses
#4
Mona Hichert, Dick H Plettenburg
BACKGROUND: Body-powered prosthesis users frequently complain about the poor cosmesis and comfort of the traditional shoulder harness. The Ipsilateral Scapular Cutaneous Anchor System offers an alternative, but it remains unclear to what extent it affects the perception and control of cable operation forces compared to the traditional shoulder harness. OBJECTIVE: To compare cable force perception and control with the figure-of-nine harness versus the Ipsilateral Scapular Cutaneous Anchor System and to investigate force perception and control at different force levels...
March 1, 2017: Prosthetics and Orthotics International
https://www.readbyqxmd.com/read/28318076/uk-policy-statements-on-testosterone-deficiency
#5
Geoffrey Hackett, Michael Kirby, David Edwards, T Hugh Jones, Jonathan Rees, Asif Muneer
To address widespread media and scientific concerns over the appropriate treatment of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British Society for Sexual Medicine developed eight consensus statements, based on current scientific evidence to address these controversial issues. These statements were in no-way designed to replace the published evidence-based guidelines on the subject developed by various professional organisations, but to provide specific answers to several current controversial issues...
March 20, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28317988/using-single-nanoparticle-tracking-obtained-by-nanophotonic-force-microscopy-to-simultaneously-characterize-nanoparticle-size-distribution-and-nanoparticle-surface-interactions
#6
Delyan R Hristov, Dong Ye, Joao Medeiros de Araújo, Colby Ashcroft, Brian DiPaolo, Robert Hart, Christopher Earhart, Hender Lopez, Kenneth A Dawson
Comprehensive characterization of nanomaterials for medical applications is a challenging and complex task due to the multitude of parameters which need to be taken into consideration in a broad range of conditions. Routine methods such as dynamic light scattering or nanoparticle tracking analysis provide some insight into the physicochemical properties of particle dispersions. For nanomedicine applications the information they supply can be of limited use. For this reason, there is a need for new methodologies and instruments that can provide additional data on nanoparticle properties such as their interactions with surfaces...
March 20, 2017: Nanoscale
https://www.readbyqxmd.com/read/28317651/clinical-validity-of-presynaptic-dopaminergic-imaging-with%C3%A2-123-i-ioflupane%C3%A2-and-noradrenergic-imaging-with-123-i-mibg-in-the-differential-diagnosis-between-alzheimer-s-disease-and-dementia-with-lewy-bodies-in-the-context-of-a-structured-5-phase-development
#7
REVIEW
Ida Sonni, Osman Ratib, Marina Boccardi, Agnese Picco, Karl Herholz, Flavio Nobili, Andrea Varrone
The use of biomarkers (BMs) for accurate diagnosis of Alzheimer's disease (AD) has been proposed by recent diagnostic criteria; however, their maturity is not sufficient to grant implementation in the clinical routine. A proper diagnostic process requires not only confirmation of the disease but also the exclusion of similar disorders entering differential diagnosis, like dementia with Lewy bodies (DLB). This review is aimed at evaluating the clinical validity of (123)I-ioflupane brain single photon emission tomography and (123)I-MIBG cardiac scintigraphy as imaging BMs for DLB...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317650/clinical-validity-of-increased-cortical-uptake-of-amyloid-ligands-on-pet-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#8
REVIEW
Konstantinos Chiotis, Laure Saint-Aubert, Marina Boccardi, Anton Gietl, Agnese Picco, Andrea Varrone, Valentina Garibotto, Karl Herholz, Flavio Nobili, Agneta Nordberg
The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317649/clinical-validity-of-cerebrospinal-fluid-a%C3%AE-42-tau-and-phospho-tau-as-biomarkers-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#9
REVIEW
Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson
Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317648/clinical-validity-of-brain-fluorodeoxyglucose-positron-emission-tomography-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#10
REVIEW
Valentina Garibotto, Karl Herholz, Marina Boccardi, Agnese Picco, Andrea Varrone, Agneta Nordberg, Flavio Nobili, Osman Ratib
The use of Alzheimer's disease (AD) biomarkers is supported in diagnostic criteria, but their maturity for clinical routine is still debated. Here, we evaluate brain fluorodeoxyglucose positron emission tomography (FDG PET), a measure of cerebral glucose metabolism, as a biomarker to identify clinical and prodromal AD according to the framework suggested for biomarkers in oncology, using homogenous criteria with other biomarkers addressed in parallel reviews. FDG PET has fully achieved phase 1 (rational for use) and most of phase 2 (ability to discriminate AD subjects from healthy controls or other forms of dementia) aims...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317647/clinical-validity-of-medial-temporal-atrophy-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#11
REVIEW
Mara Ten Kate, Frederik Barkhof, Marina Boccardi, Pieter Jelle Visser, Clifford R Jack, Karl-Olof Lovblad, Giovanni B Frisoni, Philip Scheltens
Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317646/clinical-validity-of-delayed-recall-tests-as-a-gateway-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#12
REVIEW
Chiara Cerami, Bruno Dubois, Marina Boccardi, Andreas U Monsch, Jean Francois Demonet, Stefano F Cappa
Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317645/the-biomarker-based-diagnosis-of-alzheimer-s-disease-2-lessons-from-oncology
#13
REVIEW
Marina Boccardi, Valentina Gallo, Yutaka Yasui, Paolo Vineis, Alessandro Padovani, Urs Mosimann, Panteleimon Giannakopoulos, Gabriel Gold, Bruno Dubois, Clifford R Jack, Bengt Winblad, Giovanni B Frisoni, Emiliano Albanese
Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317644/the-biomarker-based-diagnosis-of-alzheimer-s-disease-1-ethical-and-societal-issues
#14
REVIEW
Corinna Porteri, Emiliano Albanese, Charles Scerri, Maria C Carrillo, Heather M Snyder, Birgitta Martensson, Mark Baker, Ezio Giacobini, Marina Boccardi, Bengt Winblad, Giovanni B Frisoni, Samia Hurst
There is great interest in the use of biomarkers to assist in the timely identification of Alzheimer's disease (AD) in individuals with mild symptoms. However, the inclusion of AD biomarkers in clinical criteria poses socioethical challenges. The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers was established to deliver a systematic strategic research agenda (aka roadmap) to promote efficient and effective validation of AD biomarkers and to foster their uptake in clinical practice. In this article, we summarize the workshop discussion of the Geneva Task Force "ethical and societal issues" working group, which comprised bioethicists, clinicians, health economists, and representatives of those affected by AD...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317643/biomarkers-for-the-diagnosis-of-alzheimer-s-disease-in-clinical-practice-an-italian-intersocietal-roadmap
#15
Giovanni B Frisoni, Daniela Perani, Stefano Bastianello, Gaetano Bernardi, Corinna Porteri, Marina Boccardi, Stefano F Cappa, Marco Trabucchi, Alessandro Padovani
Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28315756/interleukin-4-is-a-participant-in-the-regulation-of-depressive-like-behavior
#16
Simone Wachholz, Alexandra Knorr, Leonie Mengert, Jennifer Plümper, Rainer Sommer, Georg Juckel, Astrid Friebe
Inflammatory immune activation has been frequently associated with the development of major depression. Microglia might serve as an important interface in this immune system-to-brain communication. Interleukin-4, the major Th2 type cytokine, might be protective against depression due to its ability to counter-regulate inflammation and to inhibit serotonin transporter activity. By using an Interferon-α mouse model, we show that a decreased IL-4 responsiveness of microglia was specifically related to the development of depressive-like behavior...
March 15, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28315732/2017-aha-acc-focused-update-of-the-2014-aha-acc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines
#17
Rick A Nishimura, Catherine M Otto, Robert O Bonow, Blase A Carabello, John P Erwin, Lee A Fleisher, Hani Jneid, Michael J Mack, Christopher J McLeod, Patrick T O'Gara, Vera H Rigolin, Thoralf M Sundt, Annemarie Thompson
No abstract text is available yet for this article.
March 10, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28315696/auditory-deficits-in-amusia-extend-beyond-poor-pitch-perception
#18
Kelly L Whiteford, Andrew J Oxenham
Congenital amusia is a music perception disorder believed to reflect a deficit in fine-grained pitch perception and/or short-term or working memory for pitch. Because most measures of pitch perception include memory and segmentation components, it has been difficult to determine the true extent of pitch processing deficits in amusia. It is also unclear whether pitch deficits persist at frequencies beyond the range of musical pitch. To address these questions, experiments were conducted with amusics and matched controls, manipulating both the stimuli and the task demands...
March 15, 2017: Neuropsychologia
https://www.readbyqxmd.com/read/28315622/subclinical-atherosclerosis-statin-eligibility-and-outcomes-in-african-american-individuals-the-jackson-heart-study
#19
Ravi V Shah, Aferdita Spahillari, Stanford Mwasongwe, J Jeffrey Carr, James G Terry, Robert J Mentz, Daniel Addison, Udo Hoffmann, Jared Reis, Jane E Freedman, Joao A C Lima, Adolfo Correa, Venkatesh L Murthy
Importance: Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our knowledge, in large African American populations. Objective: To compare the relative accuracy of US Preventive Services Task Force (USPSTF) and American College of Cardiology/American Heart Association (ACC/AHA) recommendations in identifying African American individuals with subclinical and clinical atherosclerotic cardiovascular disease (ASCVD)...
March 18, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28315530/cancer-moonshot-what-it-means-for-patients
#20
Deborah K Mayer, Shelley Fuld Nasso
You may have heard of the National Cancer Moonshot Initiative led by former Vice President Joe Biden. It has brought together many people through a task force, blue ribbon panel, and many public forums to discuss how best "to dramatically accelerate efforts to prevent, diagnose, and treat cancer - to achieve a decade's worth of progress in 5 years." This initiative was launched after the 2016 State of the Union address, and the task force delivered recommendations to President Barack Obama on October 17, 2016, providing an opportunity to accelerate progress against cancer...
April 1, 2017: Clinical Journal of Oncology Nursing
keyword
keyword
5891
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"